We are live on ! Find out more
AERI

Aerie Pharmaceuticals
AERI

Delisted

AERI was delisted on the 18th of November, 2022.

Back to rankings

0 hedge funds and large institutions have $0 invested in Aerie Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 153 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 156 → 0 (-156)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $703M → $0 (-$703M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 153

Holders
–
Holders Change
-156
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
153
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$73.5M
2
BlackRock
BlackRock
New York
-$53.6M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$36.9M
4
UBS Group
UBS Group
Switzerland
-$36.4M
5
WIC
Water Island Capital
New York
-$31.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
ECM
76
ExodusPoint Capital Management
New York
– -$720K -47,605 Closed
Two Sigma Investments
77
Two Sigma Investments
New York
– -$719K -47,529 Closed
Nomura Holdings
78
Nomura Holdings
Japan
– -$709K -46,893 Closed
JF
79
Jump Financial
Illinois
– -$694K -45,846 Closed
Stifel Financial
80
Stifel Financial
Missouri
– -$691K -45,665 Closed
GI
81
GAMCO Investors
Connecticut
– -$682K -45,050 Closed
Voloridge Investment Management
82
Voloridge Investment Management
Florida
– -$679K -44,846 Closed
State of Wisconsin Investment Board
83
State of Wisconsin Investment Board
Wisconsin
– -$674K -44,561 Closed
BFM
84
Boothbay Fund Management
New York
– -$614K -40,600 Closed
MAM
85
Martingale Asset Management
Massachusetts
– -$580K -38,299 Closed
Natixis Advisors
86
Natixis Advisors
Massachusetts
– -$565K -37,375 Closed
Allspring Global Investments
87
Allspring Global Investments
North Carolina
– -$543K -35,952 Closed
Mirae Asset Global Investments
88
Mirae Asset Global Investments
South Korea
– -$530K -35,026 Closed
CSS
89
Cubist Systematic Strategies
Connecticut
– -$489K -32,335 Closed
AQR Capital Management
90
AQR Capital Management
Connecticut
– -$463K -30,590 Closed
Barclays
91
Barclays
United Kingdom
– -$459K -30,316 Closed
T. Rowe Price Associates
92
T. Rowe Price Associates
Maryland
– -$428K -28,234 Closed
VF
93
Virtu Financial
New York
– -$380K -25,101 Closed
MIM
94
MetLife Investment Management
New Jersey
– -$367K -24,261 Closed
Allianz Asset Management
95
Allianz Asset Management
Germany
– -$365K -24,100 Closed
Verition Fund Management
96
Verition Fund Management
Connecticut
– -$352K -23,275 Closed
PCM
97
PenderFund Capital Management
British Columbia, Canada
– -$480K -22,950 Closed
Principal Financial Group
98
Principal Financial Group
Iowa
– -$344K -22,706 Closed
AIG
99
American International Group
New York
– -$342K -22,574 Closed
HBW
100
Hazlett, Burt & Watson
West Virginia
– -$338K -22,200 Closed
2 3
4
5 6

AERI Hedge Fund Activity: Q4 2022 in Review

0 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q4 2022, worth a combined $0 — down 100% from $703M a quarter earlier.

Sellers outnumbered buyers: 153 funds closed out of AERI and 0 opened new positions — a net loss of 153 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Deerfield Management, exiting entirely with an estimated $73.5M sold.

  • 0 institutional investors held Aerie Pharmaceuticals (AERI) as of Q4 2022, down from 156 in Q3 2022.
  • Funds reported $0 of Aerie Pharmaceuticals stock for Q4 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Aerie Pharmaceuticals positions in Q4 2022 and 153 closed out, a net change of -153 holders.
  • The largest Aerie Pharmaceuticals seller in Q4 2022 was Deerfield Management, an estimated $73.5M sold.

Based on aggregated 13F filings for Q4 2022.